{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:29:40Z","timestamp":1790303380012,"version":"4.1.0"},"reference-count":34,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,10,2]]},"published-print":{"date-parts":[[2026,1]]},"DOI":"10.2967\/jnumed.125.270755","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:25:15Z","timestamp":1762449915000},"page":"43-48","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic Performance of [\n                    <sup>18<\/sup>\n                    F]PSMA-1007 PET\/CT on Proven PSMA-Positive Hepatocellular Carcinoma: A Prospective Clinical Study"],"prefix":"10.2967","volume":"67","author":[{"given":"Kerstin","family":"Michalski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian P.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Kosmala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Kalogirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten A.","family":"Bley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Meining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Weich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"2026010206300899000_67.1.43.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026010206300899000_67.1.43.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"2026010206300899000_67.1.43.3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29913"},{"key":"2026010206300899000_67.1.43.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.214833"},{"key":"2026010206300899000_67.1.43.5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/RLU.0000000000002701","article-title":"Evidence of prostate-specific membrane antigen expression in hepatocellular carcinoma using 68Ga-PSMA PET\/CT","volume":"44","author":"Kuyumcu","year":"2019","journal-title":"Clin Nucl Med."},{"key":"2026010206300899000_67.1.43.6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4274\/mirt.galenos.2021.92053","article-title":"68Ga-PSMA PET\/CT versus 18F-FDG PET\/CT for imaging of hepatocellular carcinoma","volume":"30","author":"Gundogan","year":"2021","journal-title":"Mol Imaging Radionucl Ther."},{"key":"2026010206300899000_67.1.43.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.257915"},{"key":"2026010206300899000_67.1.43.8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00259-020-05017-0","article-title":"[68Ga]Ga-prostate-specific membrane antigen PET\/CT: a novel method for imaging patients with hepatocellular carcinoma","volume":"48","author":"Kunikowska","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300899000_67.1.43.9","first-page":"472","article-title":"Histopathologic correlation with Ga PSMA PET\/CT in non prostate tumors [abstract]","volume":"61(suppl 1)","author":"Vargas","year":"2020","journal-title":"J Nucl Med."},{"key":"2026010206300899000_67.1.43.10","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep4.1861","article-title":"PSMA as a theranostic target in hepatocellular carcinoma: immunohistochemistry and Ga-PSMA-11 PET using cyclotron-produced ga","volume":"6","author":"Thompson","year":"2022","journal-title":"Hepatol Commun."},{"key":"2026010206300899000_67.1.43.11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/tomography9010011","article-title":"Comparison between PSMA PET\/CT and MRI for characterizing: a real-world study","volume":"9","author":"Wong","year":"2023","journal-title":"Tomography."},{"key":"2026010206300899000_67.1.43.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.195172"},{"key":"2026010206300899000_67.1.43.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.37894","article-title":"18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging","volume":"10","author":"Werner","year":"2020","journal-title":"Theranostics."},{"key":"2026010206300899000_67.1.43.14","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports","volume":"48","author":"Uijen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300899000_67.1.43.15","first-page":"138","article-title":"Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue [in German]","volume":"8","author":"Remmele","year":"1987","journal-title":"Pathologe."},{"key":"2026010206300899000_67.1.43.16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/ph10040077","article-title":"Procedures for the GMP-compliant production and quality control of [18F]PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer","volume":"10","author":"Cardinale","year":"2017","journal-title":"Pharmaceuticals."},{"key":"2026010206300899000_67.1.43.17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol."},{"key":"2026010206300899000_67.1.43.18","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2019"},{"key":"2026010206300899000_67.1.43.19","first-page":"S389","article-title":"Beth Israel plugin for FIJI: a free and open source software tool for PET\/CT processing in research [abstract]","volume":"43(suppl)","author":"Kanoun","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300899000_67.1.43.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242057"},{"key":"2026010206300899000_67.1.43.21","unstructured":"Radiology ACo. CT\/MRI LI-RADS\u00ae v2018 CORE. Sitecore website. https:\/\/edge.sitecorecloud.io\/americancoldf5f-acrorgf92a-productioncb02-3650\/media\/ACR\/Files\/RADS\/LI-RADS\/LI-RADS-CT-MRI-2018-Core.pdf. Accessed October 23, 2025."},{"key":"2026010206300899000_67.1.43.22","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132"},{"key":"2026010206300899000_67.1.43.23","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.3390\/cancers16223865","article-title":"Prostate-specific membrane antigen (PSMA) PET\/CT in the detection and diagnosis of hepatocellular carcinoma (HCC): a systematic review and meta-analysis","volume":"16","author":"Hannah","year":"2024","journal-title":"Cancers (Basel)."},{"key":"2026010206300899000_67.1.43.24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4254\/wjh.v5.i8.417","article-title":"Imaging appearance of treated hepatocellular carcinoma","volume":"5","author":"Agnello","year":"2013","journal-title":"World J Hepatol."},{"key":"2026010206300899000_67.1.43.25","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.18632\/oncotarget.27024","article-title":"Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging","volume":"10","author":"Tolkach","year":"2019","journal-title":"Oncotarget."},{"key":"2026010206300899000_67.1.43.26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/cancers11030316","article-title":"Tumor neovascularization and developments in therapeutics","volume":"11","author":"Katayama","year":"2019","journal-title":"Cancers (Basel)."},{"key":"2026010206300899000_67.1.43.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"2026010206300899000_67.1.43.28","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070"},{"key":"2026010206300899000_67.1.43.29","doi-asserted-by":"crossref","first-page":"Lba4008","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW","volume":"42","author":"Galle","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026010206300899000_67.1.43.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00961-3"},{"key":"2026010206300899000_67.1.43.31","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA. Oncol."},{"key":"2026010206300899000_67.1.43.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2026010206300899000_67.1.43.33","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02551-0"},{"key":"2026010206300899000_67.1.43.34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02575-3"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T14:30:29Z","timestamp":1767364229000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,2]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.2967\/jnumed.125.270755"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270755","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}